Boston Scientific announced its first deal of 2025. On January 8, Boston Scientific reported that it was acquiring the remaining 74% stake of Bolt Medical for $443 million, plus potential regulatory milestone payments of up to $221 million.
Bolt Medical is based in Carlsbad, California. It is a developer and manufacturer of an intravascular lithotripsy advanced laser-based platform for treating coronary and peripheral artery disease. The company is concurrently studying three unique catheter platforms for various arterial vessel beds. Boston Scientific helped establish Bold Medical in 2019 and prior to this transaction owned a 26% stake in the company.
With headquarters in Marlborough, Massachusetts, Boston Scientific develops and manufactures minimally invasive medical devices used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology and gynecology. According to its full-year 2023 financial report, the company generated net sales of $14.2 billion and annual EBITDA of $3.6 billion.
The acquisition includes an upfront payment of $443 million for the 74% stake not yet owned, plus potential regulatory milestone payments of up to $221 million.
According to data in the LevinPro HC database, this transaction marks the second Medical Devices acquisition of 2025. There were 87 Medical Devices transactions reported in 2024, 112 announced in 2023 and 124 announced in 2022.
